Elicio Therapeutics (NASDAQ:ELTX - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "strong sell" rating to a "sell" rating in a note issued to investors on Saturday.
Several other analysts have also issued reports on the stock. B. Riley Financial assumed coverage on shares of Elicio Therapeutics in a research report on Wednesday, June 10th. They issued a "buy" rating and a $27.00 price target on the stock. HC Wainwright raised their target price on Elicio Therapeutics from $17.00 to $23.00 and gave the stock a "buy" rating in a research report on Monday, June 15th. JonesTrading downgraded shares of Elicio Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, June 16th. Rodman & Renshaw restated a "buy" rating on shares of Elicio Therapeutics in a research note on Monday, June 15th. Finally, LADENBURG THALM/SH SH assumed coverage on shares of Elicio Therapeutics in a report on Thursday, June 18th. They set a "buy" rating and a $12.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Elicio Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $19.75.
View Our Latest Stock Analysis on Elicio Therapeutics
Elicio Therapeutics Stock Performance
Shares of ELTX opened at $3.09 on Friday. The company has a market capitalization of $58.99 million, a PE ratio of -1.42 and a beta of 1.30. Elicio Therapeutics has a one year low of $2.66 and a one year high of $16.00. The company has a debt-to-equity ratio of 5.75, a current ratio of 2.24 and a quick ratio of 2.24. The company's fifty day moving average price is $4.46 and its 200 day moving average price is $8.43.
Elicio Therapeutics (NASDAQ:ELTX - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.43) earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.11. As a group, analysts expect that Elicio Therapeutics will post -2.08 earnings per share for the current year.
Institutional Investors Weigh In On Elicio Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Royal Bank of Canada bought a new stake in Elicio Therapeutics during the 1st quarter worth about $225,000. Jane Street Group LLC acquired a new stake in Elicio Therapeutics during the 1st quarter worth $92,000. Geode Capital Management LLC raised its position in shares of Elicio Therapeutics by 56.0% during the second quarter. Geode Capital Management LLC now owns 120,831 shares of the company's stock worth $933,000 after purchasing an additional 43,364 shares during the period. Raymond James Financial Inc. acquired a new stake in Elicio Therapeutics during the 2nd quarter worth approximately $46,000. Finally, Vanguard Group Inc. raised its holdings in shares of Elicio Therapeutics by 4.2% during the third quarter. Vanguard Group Inc. now owns 473,859 shares of the company's stock worth $5,184,000 after acquiring an additional 19,240 shares during the period. 35.03% of the stock is owned by institutional investors and hedge funds.
Elicio Therapeutics Company Profile
(
Get Free Report)
Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Elicio Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elicio Therapeutics wasn't on the list.
While Elicio Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
